These consortia vary in their scope, funding, and structure from government-funded models such as the National Cancer Institute Experimental Therapeutics Clinical ... Open Payments is a public ...
Before joining Acceleron, she had roles of increasing responsibility at Mersana Therapeutics, Shire ... and others should note that we communicate with our investors and the public using our company ...
as well as mid-size public biopharmaceutical companies such as Alector, Cullinan Therapeutics, Innovent, iTeos, Mersana, Scholar Rock, and others. Adimab’s integrated antibody discovery and ...
In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s ...
Hosted on MSN5d
William Blair Initiates Coverage of Mersana Therapeutics (MRSN) with Outperform RecommendationFintel reports that on February 6, 2025, William Blair initiated coverage of Mersana Therapeutics (NasdaqGS:MRSN) with a ...
Mersana Therapeutics, Inc. CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and ...
William Blair analyst Andy Hsieh last night initiated coverage of Mersana Therapeutics (MRSN) with an Outperform rating. The firm believes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback